Enhance Efficacy to Meet Functional Endpoints & Prioritize Earlier Intervention to Deliver Best in Class Therapies for Dry AMD
This Event Has Now Run
Revolutionizing Dry AMD Treatment
There’s significant momentum in the clinical and preclinical pipeline for dry AMD, backed by record-breaking investments and acquisitions. This was further demonstrated by the landmark first approval in February this year. The question for the field now is - what's next?
Uniting 60+ experts across biotech and pharma who are actively developing drugs that have the potential to revolutionize treatment of dry AMD, the 4th Annual Dry AMD Therapeutic Development Summit is back this November to answer that very question.
Dry AMD therapeutic development is the hottest topic in the ocular space right now. Join us to accelerate the drug pipeline and revolutionize dry AMD treatment for millions of patients in the US and worldwide.
“IVERIC BIO, Inc. is delighted to speak at the 2023 Annual Dry AMD Therapeutic Development Summit. This esteemed platform provides us with the invaluable opportunity to showcase our revolutionary regulatory strategies, aimed at expediting and optimizing the development of safe, efficacious, and high-quality therapeutics for Dry Age-related Macular Degeneration treatment.”
On Wednesday, November 15 (Day 1), IVERIC BIO will give a comprehensive guide to crafting a successful Regulatory Affairs strategy, emphasizing the importance of collaboration with the FDA and providing actionable insights to enhance the approval process while minimizing regulatory hurdles. It is a must-attend event for professionals involved in regulatory affairs, pharmaceuticals, medical devices, and biotechnology industries.
World Class 2023 Expert Speaker Faculty Included:
Chief Executive Officer
Lineage Cell Therapeutic
Senior Director & Clinical Leader, Early Development & Translational Medicine
Director - Clinical Development & Medical Affairs
Our 2023 Partners:
Hear What Our Previous Attendees Had To Say:
"The speakers, sessions and planning around the meeting was excellent."
Biogen - Dry AMD Therapeutic Development Attendee
“Great talks and intimate conference allowed for insightful networking opportunities."
Homology Medicines - Dry AMD Therapeutic Development Attendee
“The intimate environment and wonderful facilitators made for a more honest and engaging meeting."
Qureator - Dry AMD Therapeutic Development Attendee
“The speakers are highly knowledgeable in this disease area and the meeting was informative.’’
Astellas Innovation Management - Dry AMD Therapeutic Development Attendee